In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Minimally-Invasive Heart Valves, Edwards Cuts a Wide Swath

Executive Summary

Heart valves used in surgical procedures constitute more than 40% of the revenues of Edwards Lifesciences. So the company's recent acquisition of endovascular heart valve company Percutaneous Valve Technologies Inc. (PVT), along with its earlier acquisition of a percutaneous heart valve from Jomed NV, could be regarded as part of its plan to launch a pre-emptive strike. Edwards now has the broadest and most advanced portfolio of endovascular heart valve repair products in the industry. It thus hedges itself against the possible future erosion of its surgical valve franchise by the new interventional cardiology-oriented approaches and beats out Medtronic and Boston Scientific, each of which previously held 10% stakes in PVT before the acquisition.

You may also be interested in...



Evalve: Leading the Valve Revolution

Full-scale commercialization of percutaneous heart valve technology is still years away, but Evalve's new approach to mitral repair is closest to the clinic.

Edwards: Battling the Innovator's Dilemma

Having built a franchise serving cardiac surgeon, Edwards is looking to maintain its market leadership by both expanding into peripherals and embracing interventionalists.

Edwards: Battling the Innovator's Dilemma

Having built a franchise serving cardiac surgeon, Edwards is looking to maintain its market leadership by both expanding into peripherals and embracing interventionalists.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV002224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel